1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) - Market Insights, Epidemiology, and Market Forecast-2028

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) - Market Insights, Epidemiology, and Market Forecast-2028

  • January 2020
  • 158 pages
  • ID: 5842605
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) - Market Insights, Epidemiology, and Market Forecast-2028’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PF-ILD in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
PF-ILD is a collective term used for indications that share a common progressive phenotype. The phenotype is characterized by worsening respiratory symptoms, lung function decline, limited response to immune-modulatory therapies, decreased quality of life, and potentially, early death. Interstitial lung disease (ILD) encompasses a large group of more than 200 parenchymal pulmonary disorders, of which the majority are classified as rare. ILD is further classifies into various types and subtypes. The major classification includes idiopathic interstitial pneumonia (IIPs), autoimmune ILDs, hypersensitivity pneumonitis (HP), sarcoidosis, and several other ILDs. Further, IIP is classified into idiopathic pulmonary fibrosis (IPF)—which contributes to the majority of the cases—, iNSIP, unclassifiable IIPs, and others IIPs. Autoimmune ILDs are classified into IPAF, RA-ILD, SSc-ILD, and other autoimmune ILDs.
According to the analyst’s, the patient pool of PF-ILD includes the cases of IPF, iNSIP, unclassifiable IIPs, IPAF, RA-ILD, SSc-ILD, HP, sarcoidosis and other ILDs related to occupational exposures.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2028
Progressive-Fibrosing Interstitial Lung Disease–Disease Understanding
PF-ILDs is characterized by worsening respiratory symptoms, lung function decline, limited response to immune-modulatory therapies, decreased quality of life, and potentially, early death. Irrespective of the clinical diagnosis, these PF-ILDs show commonalities in the underlying pathogenetic mechanisms that drive a self-sustaining process of pulmonary fibrosis.

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Interstitial Lung Disease (ILD) in the 7MM, Type-specific Prevalent Cases of Interstitial Lung Disease (ILD) in the 7MM, Subtype-specific Prevalent Cases of Interstitial Lung Disease (ILD) in the 7MM, and Total Prevalent Cases of PF-ILD in the 7MM) scenario of PF-ILD in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017–2028.
According to the analyst’s, the total prevalent population of Interstitial Lung Disease in seven major markets was 736,184 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2028).
The total prevalent population of PF-ILD in seven major markets was 228,613 in 2017.

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Drug Chapters
Evidence-based treatment for PFILDs patients’ are currently limited, and often receive corticosteroids and/or off-label immunosuppressive therapy with a variable outcome. Because of commonalities between IPF and PF-ILDs, it has been proposed that the potential efficacy and tolerability of antifibrotic drugs, like pirfenidone and nintedanib, should be evaluated in PF-ILDs. By far, the most commonly used first-line therapy for all the non-IPF fibrosing ILDs was corticosteroids. Because PF-ILDs have been defined by progression despite conventional therapy, there is inherently a substantial unmet need for the treatment of these conditions. Antifibrotic drugs effective to slow down disease progression in IPF may conceivably have comparable efficacy in other PF-ILDs.
Not many companies are working on this patient pool. Currently, two companies, i.e., Boehringer Ingelheim and Roche are investigating their potential molecules to provide treatment of PF-ILD. Nintedanib (Ofev) and Pirfenidone (Esbriet) is under development for PF-ILD. Both the drugs are approved for IPF and are being tested to know whether they can be a potential approach for PF-ILD. Pirfenidone is under development for SSc-ILD as well, but recently, it was reported that it does not stabilize or improve lung function in patients with SSc-ILD. The failure of pirfenidone can be proved a boon for nintedanib, and hence it is expected that nintedanib will generate a major market revenue than pirfenidone.

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Market Outlook
According to the analyst, the total market size of PF-ILDs in seven major markets was USD 233.19 million in 2017. The market size of PF-ILD is expected to increase at a significant CAGR during the study period (2017–2028).
Among all the seven major markets, the United States accounts for the highest market size of PF-ILD. In 2017, the market size of PF-ILD was found to be USD 158.73 million.

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Drugs Uptake
The current market size of PF-ILD is mainly attributed by corticosteroids, mycophenolate mofetil, azathioprine, cyclosporine, tacrolimus, and cyclophosphamide. The market size is expected to increase during the forecast period (2019–2028), due to potential therapies nintedanib (Ofev) and pirfenidone (Esbriet).

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Report Insights
• Patient Population by total prevalent cases of ILD
• Type-specific prevalent cases of ILD
• Subtype-specific prevalent cases of ILD
• Prevalent cases of PF-ILD
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation

• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This report will help to develop Business Strategies by understanding the trends shaping and driving PF-ILD market
• Organize sales and marketing efforts by identifying the best opportunities for PF-ILD market
• To understand the future market competition in the PF-ILD market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology forecast- 2030

  • $ 4750
  • August 2021
  • 180 pages

‘Chronic Obstructive Pulmonary Disease (COPD)—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted ...

  • United States
  • Spain
  • Respiratory Disease
  • Industry analysis
  • Chronic Obstructive Pulmonary Disease Prevalence

ref:plp2019

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on